Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00061113 · ClinicalTrials.gov registry record · Phase 4

Substance Dependent Teens - Impact of Treating Depression Study 1 - 1

A Phase 4 study, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 4
Development phase
126
Enrollment target

NCT00061113 is a Phase 4 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 126 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00061113, a Phase 4 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 4
Development phase
126 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the impact of treating depression on substance dependent teens.

Interventions

  • DRUG fluoxetine
  • DRUG Fluoxetine + outpatient cognitive behavioral therapy
  • DRUG placebo + CBT

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2001-02
Est. Completion 2006-08
Phase Phase 4

What the Registry Record Tells You About NCT00061113

The ClinicalTrials.gov registry entry for NCT00061113 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which fluoxetine is the first listed.

NCT00061113 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00061113 about?

NCT00061113 is a clinical study titled "Substance Dependent Teens - Impact of Treating Depression Study 1 - 1". The purpose of this study is to evaluate the impact of treating depression on substance dependent teens.

What is the current status of trial NCT00061113?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 126 participants. The study started on 2001-02. Estimated completion is 2006-08.

What interventions are being tested in trial NCT00061113?

The interventions under investigation include: fluoxetine (DRUG), Fluoxetine + outpatient cognitive behavioral therapy (DRUG), placebo + CBT (DRUG).

Who is sponsoring clinical trial NCT00061113?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.